Onesource Specialty Pharma (ONESOURCE.NS) Stock Price

Onesource Specialty Pharma Price

CLOSED
1,366.60
​
Market closed

Revenue has compounded at 232.4% per year over the past 3 years to 14.22 B INR. Onesource Specialty Pharma's net margin stands at -5.2%, up from -2,066.0% several years earlier. Analysts set a median price target of 2,153.22 INR, implying 57.6% above the current price. Of 8 analysts, 6 rate the stock a buy — an overall Buy consensus.

Onesource Specialty Pharma stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Onesource Specialty Pharma business model & stock analysis

Onesource Specialty Pharma Ltd, headquartered in Bangalore, India, operates in the Health Care sector within the Life Sciences Tools & Services industry. The company, listed on 24 January 2025, employs 525 full-time staff and functions as a vertically integrated biopharma CDMO. It specializes in developing and manufacturing complex biologics, biosimilars, and vaccines, with expertise in prefilled syringes, autoinjectors, and advanced delivery systems for cell and gene therapies and RNA products. Its integrated services support comprehensive biologics development and production.

Frequently asked questions about Onesource Specialty Pharma

Analysts currently set an average price target of 2,094.06 INR for the Onesource Specialty Pharma stock (median: 2,153.22 INR), implying +48.7 % versus the latest price. The consensus is based on 8 analyst ratings.

8 analysts currently rate the Onesource Specialty Pharma stock: 6 recommend buying, 1 holding and 1 selling.

Converted at the current exchange rate, the Onesource Specialty Pharma share trades at 12.81 EUR (1,366.60 INR).

The revenue of Onesource Specialty Pharma is 14.22 B INR. This figure is based on current financial data and reflects the company's business performance.

The profit of Onesource Specialty Pharma is -738.03 M INR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Onesource Specialty Pharma is currently -212.28. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Onesource Specialty Pharma stock.

The price-to-sales ratio (P/S) of Onesource Specialty Pharma is currently 11.02. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Onesource Specialty Pharma stock.

The Eulerpool Quality Score for Onesource Specialty Pharma is 1/10.

The ISIN of Onesource Specialty Pharma is INE013P01021. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Onesource Specialty Pharma is ONESOURCE.NS. The ticker symbol is used to trade Onesource Specialty Pharma shares on the stock exchange.

Fair ValueTerminal
1,202.61 INR
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Life Sciences Tools & Services
Number of shares
Employees
Revenue per Employee
27.08 M INR
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
INR
Initial public offering
Jan 24, 2025
ISIN
INE013P01021
Cusip
Y816AG105
Market capitalization
156.64 B INRLarge Cap
52-Week Range
PEG
-15.58
P/E ratio
P/Ee 2027
37.83
P/Ee 2028
18.10
P/Ee 2029
25.78
P/Se
6.95
EV/EBIT
679.31
P/B Ratio
2.69
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-1.01 %
Last updated Oct 19, 2026, 7:40 PM

Onesource Specialty Pharma Peer Group